Showing results (61-70 of 544) with videos related to
Sort By:
Pageof 55
Journal of the American College of Cardiology|October 2, 2012
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.European Heart Journal. Acute Cardiovascular Care|February 23, 2021
Association between β-blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registryKatarina Mars, John Wallert, Claes Held, et al.JAMA|April 11, 2023
Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical TrialJohan Sundström, Lars Lind, Shamim Nowrouzi, et al.Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|March 21, 2007
A high-fat meal is accompanied by increased plasma interleukin-6 concentrationsPia Lundman, Susanna Boquist, Ann Samnegård, et al.European Heart Journal. Acute Cardiovascular Care|December 17, 2013
Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada?Nina Johnston, Anna Bornefalk-Hermansson, Karin Schenck-Gustafsson, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 18, 2015
Invasive strategies and outcomes for non-ST-segment elevation acute coronary syndromes: a twelve-year experience from SWEDEHEARTPeter Damman, Tomas Jernberg, Bertil Lindahl, et al.European Journal of Preventive Cardiology|April 13, 2012
Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY studyOla Vedin, Emil Hagström, Ralph Stewart, et al.European Journal of Clinical Investigation|January 3, 2013
Risk prediction in stable angina pectorisThomas Kahan, Lennart Forslund, Claes Held, et al.Current Cardiology Reports|April 27, 2012
Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?Christoph Varenhorst, Stefan JamesPageof 55